Clinical Research Directory
Browse clinical research sites, groups, and studies.
TAF to Prevent HBV Reactivation in Cancer Patients
Sponsor: Chiayi Christian Hospital
Summary
Tenofovir alafenamide (TAF) has been approved to prevent HBV reactivation for HBsAg-positive cancer patients receiving chemotherapy. However, the real-world effectiveness and safety of TAF for cancer patients was lacing. Therefore, we conduct a prospective single arm study to evaluate the efficacy and safety of TAF as a prophylactic antiviral agent for HBsAg-positive cancer patients receiving chemotherapy.
Official title: The Efficacy and Safety of TAF as a Prophylactic Antiviral Agent for HBsAg-positive Cancer Patients Receiving Chemotherapy
Key Details
Gender
All
Age Range
20 Years - Any
Study Type
INTERVENTIONAL
Enrollment
102
Start Date
2021-07-01
Completion Date
2024-12-31
Last Updated
2024-11-12
Healthy Volunteers
No
Conditions
Interventions
Tenofovir alafenamide
Tenofovir alafenamide 25 mg once per day for one year
Locations (5)
Dalin Tzu Chi General Hospital
Chiayi City, Taiwan
Ditmanson Medical Foundation Chiayi Christian Hospital
Chiayi City, Taiwan
St. Martin De Porress Hospital
Chiayi City, Taiwan
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan
Chi Mei Medical Hospital
Tainan, Taiwan